Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
$2.94
+2.1%
$3.33
$1.72
$3.84
$27.63M1.4926,275 shs8,422 shs
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$56.00
$55.66
$17.15
$56.48
$1.14B2.34301,073 shsN/A
NVH
Novoheart
C$0.53
+1.9%
C$0.53
C$0.26
C$0.72
C$99.98MN/A33,593 shs23,066 shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$2.89
+1.0%
$2.17
$0.72
$3.69
$115.98M1.29312,471 shs343,446 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
+2.08%-7.26%-13.78%+23.01%+3.14%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
0.00%0.00%0.00%0.00%+110.61%
NVH
Novoheart
0.00%0.00%0.00%0.00%0.00%
Rezolute, Inc. stock logo
RZLT
Rezolute
+1.05%-10.80%+52.91%+158.04%+40.98%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
2.5302 of 5 stars
3.55.00.00.00.60.81.3
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
N/AN/AN/AN/AN/AN/AN/AN/A
NVH
Novoheart
N/AN/AN/AN/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
3.2837 of 5 stars
3.53.00.00.03.04.20.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.00
Buy$6.00104.08% Upside
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
2.00
HoldN/AN/A
NVH
Novoheart
N/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
3.00
Buy$8.80204.50% Upside

Current Analyst Ratings

Latest ACST, CIR, NVH, and RZLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$7.00
4/18/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
4/9/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
3/7/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
2/14/2024
Rezolute, Inc. stock logo
RZLT
Rezolute
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
2/7/2024
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/A$9.14 per shareN/A
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$786.92M1.45$4.77 per share11.74$7.81 per share7.17
NVH
Novoheart
C$423.50K236.08C$0.07 per share7.46C$0.12 per share4.34
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$3.15 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$42.43M-$5.08N/AN/AN/AN/A-13.18%-11.32%6/28/2024 (Estimated)
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
$19.39M$1.3740.8819.51N/A3.40%35.32%5.21%N/A
NVH
Novoheart
N/A-C$0.04N/AN/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
-$51.79M-$1.10N/AN/AN/AN/A-51.81%-48.05%5/9/2024 (Estimated)

Latest ACST, CIR, NVH, and RZLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/13/2024Q2 2024
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.27-$0.27N/A-$0.27N/AN/A
2/12/202412/31/2023
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$0.23-$0.21+$0.02-$0.21N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/A
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
N/AN/AN/AN/AN/A
NVH
Novoheart
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/A
15.19
15.19
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
3.34
2.29
1.46
NVH
Novoheart
27.62
6.13
6.05
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
12.00
12.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
6.08%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
96.16%
NVH
Novoheart
N/A
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%

Insider Ownership

CompanyInsider Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
13.51%
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
1.00%
NVH
Novoheart
N/A
Rezolute, Inc. stock logo
RZLT
Rezolute
18.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
329.40 million8.13 millionNot Optionable
CIRCOR International, Inc. stock logo
CIR
CIRCOR International
3,06020.39 million20.19 millionOptionable
NVH
Novoheart
N/A188.64 millionN/ANot Optionable
Rezolute, Inc. stock logo
RZLT
Rezolute
5740.13 million32.83 millionNot Optionable

ACST, CIR, NVH, and RZLT Headlines

SourceHeadline
Federated Hermes Inc. Purchases 3,544,053 Shares of Rezolute, Inc. (NASDAQ:RZLT)Federated Hermes Inc. Purchases 3,544,053 Shares of Rezolute, Inc. (NASDAQ:RZLT)
marketbeat.com - April 24 at 5:43 AM
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual MeetingPhase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
globenewswire.com - April 23 at 8:00 AM
Rezolute (NASDAQ:RZLT) Now Covered by JonestradingRezolute (NASDAQ:RZLT) Now Covered by Jonestrading
americanbankingnews.com - April 20 at 4:42 AM
Rezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by JMP SecuritiesRezolute (NASDAQ:RZLT) Stock Rating Reaffirmed by JMP Securities
americanbankingnews.com - April 20 at 1:54 AM
JonesTrading Initiates Coverage of Rezolute (RZLT) with Buy RecommendationJonesTrading Initiates Coverage of Rezolute (RZLT) with Buy Recommendation
msn.com - April 19 at 8:15 AM
Rezolute (NASDAQ:RZLT) Given Market Outperform Rating at JMP SecuritiesRezolute (NASDAQ:RZLT) Given Market Outperform Rating at JMP Securities
marketbeat.com - April 18 at 2:21 PM
Jonestrading Begins Coverage on Rezolute (NASDAQ:RZLT)Jonestrading Begins Coverage on Rezolute (NASDAQ:RZLT)
marketbeat.com - April 18 at 8:35 AM
Optimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment ProspectsOptimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment Prospects
markets.businessinsider.com - April 18 at 5:30 AM
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
investorplace.com - April 15 at 3:43 PM
Rezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, PredictionsRezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, Predictions
benzinga.com - April 10 at 4:10 PM
Rezolute (NASDAQ:RZLT) Earns Buy Rating from Analysts at Maxim GroupRezolute (NASDAQ:RZLT) Earns Buy Rating from Analysts at Maxim Group
marketbeat.com - April 9 at 8:23 AM
Insiders Are Buying These 5 Penny StocksInsiders Are Buying These 5 Penny Stocks
insidermonkey.com - April 4 at 8:51 AM
Rezolute, Inc. (NASDAQ:RZLT) Short Interest UpdateRezolute, Inc. (NASDAQ:RZLT) Short Interest Update
marketbeat.com - March 27 at 9:30 PM
Rezolute Reaches US$75m Market Cap Benefiting Insider Stock BuyingRezolute Reaches US$75m Market Cap Benefiting Insider Stock Buying
finance.yahoo.com - March 27 at 8:51 AM
3 Stocks Insiders Are Buying That Analysts Love (RZLT)3 Stocks Insiders Are Buying That Analysts Love (RZLT)
insidertrades.com - March 26 at 12:55 PM
Rezolutes chief medical officer buys $18.8k in company stockRezolute's chief medical officer buys $18.8k in company stock
investing.com - March 20 at 5:29 PM
Daron Evans Buys 20,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockDaron Evans Buys 20,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock
insidertrades.com - March 20 at 7:32 AM
Brian Kenneth Roberts Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockBrian Kenneth Roberts Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock
insidertrades.com - March 19 at 5:40 AM
Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Buys 36,503 Shares of StockInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Buys 36,503 Shares of Stock
insidertrades.com - March 15 at 11:42 AM
Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires $96,500.00 in StockRezolute, Inc. (NASDAQ:RZLT) CFO Acquires $96,500.00 in Stock
insidertrades.com - March 11 at 7:22 AM
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
globenewswire.com - March 6 at 7:30 AM
Rezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning CallsRezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning Calls
benzinga.com - February 22 at 12:13 PM
Rezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateRezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
finanznachrichten.de - February 16 at 9:03 AM
Were Keeping An Eye On Rezolutes (NASDAQ:RZLT) Cash Burn RateWe're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate
finance.yahoo.com - February 15 at 7:59 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acasti Pharma logo

Acasti Pharma

NASDAQ:ACST
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
CIRCOR International logo

CIRCOR International

NYSE:CIR
CIRCOR International, Inc. designs, manufactures, and distributes flow and motion control products in Europe, the Middle East, Africa, North America, and internationally. The company has a product portfolio of brands serving its customers' demanding applications. It operates through two segments, Aerospace & Defense and Industrial. The Aerospace & Defense segment manufactures and markets control valves, pumps, regulators, fluid controls, pneumatic valves and controls, electro-mechanical controls, electric motors, and other flow control products and subsystems; propeller pumps; actuation systems; MIL-spec butterfly valves and actuators; brushless DC motors; switches; and actuation components and sub-systems. Its products and services are used in the military and defense, commercial aerospace, business and general aviation, and general industrial markets, as well as serves aircraft manufacturers and tier 1 and tier 2 suppliers. This segment offers its products under the CIRCOR Aerospace, Aerodyne Controls, CIRCOR Bodet, CIRCOR Industria, CIRCOR Motors, Hale Hamilton, Leslie Controls, Portland Valve, and Warren Pumps brands. The Industrial segment provides 3 and 2 screw pumps, progressing cavity pumps, specialty centrifugal pumps, and gear metering pumps; automatic recirculation valves; engineered valves; positive displacement pumps; general service control valves; and top and bottom unheading devices and center feed devices for the end-users and original equipment manufacturers, as well as engineering, procurement, and construction companies. This segment offers its products under the Allweiler, DeltaValve, Houttuin, IMO Pump, IMO AB, Leslie Controls, RG Lawrence, RTK, Schroedahl, TapcoEnpro, Tushaco, and Zenith brands. The company markets its solutions directly and through various sales partners to approximately 14,000 customers in approximately 100 countries. CIRCOR International, Inc. was incorporated in 1999 and is headquartered in Burlington, Massachusetts.

Novoheart

CVE:NVH
Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.
Rezolute logo

Rezolute

NASDAQ:RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.